AstraZeneca made £3bn in sales from its coronavirus jab in 2021, but has warned that revenues from Covid-19 products are set to fall over the year ahead.
The group, which is not making a profit from the vaccine, notched up £1.3bn in sales from the Covid jab in the final three months of last year alone, with 2.5 billion doses released for supply around the world over the year as a whole.
The drugs giant forecast total group sales to rise by a "high teens percentage" in 2022, but warned that Covid-19 revenues would decline by a "a low-to-mid twenties percentage".
